This disorder is an expanding area of concern in the health care system.
Many theories exist on the underlying cause of depressive disorders.
Nefazodone is one of the newest anti-depressants engineered to improve selectively aspects of central neurotransmission. Its mechanism of action is unknown. Nefazodone has three metabolites. P450 CYP IIIA4 isoenzyme in vitro. Concomitant use with any medication which is metabolized through this pathway should either ultimately be avoided or be therapeutically adjusted and closely monitored.